Safety of Extracellular Vesicles for Burn Wounds

Last updated: November 19, 2024
Sponsor: Aegle Therapeutics
Overall Status: Completed

Phase

1

Condition

Hyponatremia

Skin Wounds

Treatment

AGLE-102

Clinical Study ID

NCT05078385
AGLE-102-102
  • Ages > 18
  • All Genders

Study Summary

Treatment of patients with deep second degree burns of the skin with extracellular vesicles (EV) isolated from bone marrow derived mesenchymal stem cells.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Eighteen years of age or older with deep second degree thermal burn wounds

  2. Index burn injury within the prior 72 hours

  3. Subjects must understand and be willing and able to give written informed consent

  4. Subjects must agree to have blood draws performed per protocol

  5. Subjects must be accessible for wound treatment and assessment visits

  6. Males and females must agree to use an acceptable method of contraception.Exceptions will be females of non-childbearing age and monogamous males who arepartners of females of non-childbearing age. Acceptable methods of birth controlinclude; history of sterilization, oral contraceptives, depo-progesteroneinjections, a barrier contraceptive such as a condom with or without spermicidecream or gel, diaphragms or cervical cap with or without spermicide cream or gel, oran intrauterine device (IUD).

  7. Maximum index wound size at screening limited to single or multiple wounds (in adefined anatomical area) cumulatively ≤ 600 cm2. Minimum wound size at screening: 30cm2. Other wounds may be present that are treated separately from this protocolsubject to the maximum TBSA exclusion criteria listed below.

Exclusion

Exclusion Criteria:

  1. Solely first degree or solely third degree burns

  2. Cumulative burn area ≥ 20% TBSA (20% TBSA corresponds to 3700 cm2 in a 70 kg, 175 cmsubject)

  3. Burns that occur over a previous scar

  4. Chemical, radiation, or electrical burns

  5. Subjects with superficial second degree burn who are expected to heal within 2 weekswith standard therapy

  6. Evidence of active infection at the wound site

  7. Evidence of significant wound healing prior to treatment

  8. Burn wounds requiring surgery (other than debridement), or skin grafting

  9. Wound exclusively located in the area of fingers, toes, face, or perineum

  10. Wound that extends > 50% across one or more joints

  11. Have any requirement for the use of systemic steroids or immunosuppressivemedications

  12. Subjects allergic to human albumin, streptomycin, or penicillin

  13. Be a pregnant female or nursing mother

  14. Subjects who are known or found to be HIV positive

  15. History of alcohol or substance abuse requiring treatment within the past 12 months.

  16. Severe medical conditions

  17. Malignancy (other than non-melanoma skin cancer) not in remission or inremission less than 5 years

  18. Life expectancy less than two years

  19. Severe cardiopulmonary disease restricting ambulation to the clinical facility

  20. WBC <3 or > 20 x109/L, Hgb < 9g/dL, platelet count 100x109/L or less, serumcreatinine > 1.5 times the upper normal limit, AST or ALT > 2.4 times upper normallimit

  21. Known history of coagulopathy

  22. Subjects who have a reasonable likelihood of being a recipient of tissue or organtransplantation

  23. History of poor compliance, unreliability

Study Design

Total Participants: 1
Treatment Group(s): 1
Primary Treatment: AGLE-102
Phase: 1
Study Start date:
August 10, 2023
Estimated Completion Date:
November 19, 2024

Study Description

This study is designed to examine the safety and efficacy, in 10 patients of administration of allogeneic MSC EV to deep second degree burn wounds. The dose level delivered will be approximately 1 X 107 EV particles for each cm2 treated area. Wounds eligible for treatment will not exceed 600 cm2 per wound or collection of wounds in a defined anatomical area (e.g., arm, leg, chest) treated. Patients with 20% or greater TBSA in total (3700 cm2 in a 70 kg, 175 cm subject) will be ineligible to participate in the study. The first treatment will be administered within 48 hours of the burn injury. Two additional administrations of EV will be given approximately one week (day 5-7 post-injury) and two weeks after the first treatment (unless the wound is fully closed, in which case the patient will continue to be monitored at weekly intervals through 5 weeks, then at 8, 12, 26, and 54 weeks). Safety will be assessed by collection of adverse event data. The potential for wound healing efficacy will be evaluated by recording the percent of burns re-epithelialized within 8 weeks as well as the time to complete closure. Wound closure will be defined as complete re-epithelialization that is not subject to re-injury during dressing changes or as a result of normal daily activities (e.g., wearing clothing, eating, sleeping). The potential for tissue regeneration and restoration of pigmentation, hair growth and skin texture will be evaluated by scoring healing and scar formation using POSAS. Assessment of the potential for prevention of conversion will be done using LDI. Deep second degree wounds presenting at screening that are assessed to be deeper by LDI at the 5-7 day reading than at the initial evaluation in the first 72 hours will be considered to have undergone conversion. Exploratory endpoints will include monitoring for the presence of an immunologic response in recipients.

Connect with a study center

  • Ron Manning

    Miami, Florida 33136
    United States

    Active - Recruiting

  • Ryder Trauma Center

    Miami, Florida 33136
    United States

    Site Not Available

  • North Carolina Jaycee Burn Center

    Chapel Hill, North Carolina 27599
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.